Verastem, Inc. (VSTM) Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Verastem, Inc. NASDAQ:VSTM Healthcare · Biotechnology
CLOSED · Nov 9 $8.70 CLOSED · Nov 9 Prev close $8.41 Close $8.70 AH close $8.75 VOL 2.76M $ Vol $23.87M RVOL 0.48x
Mkt Cap $1.1B
VOL 2.76M sh
$ Vol $23.87M
RVOL 0.48×
Press Release ● Major ⚠ 5
Verastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
Verastem posted Q3 2026 net product revenue of $24.0 million, more than double the $11.2 million a year earlier, driven by strong refill growth for AVMAPKI FAKZYNJA CO-PACK.
Lead pipeline asset VS-7375 showed a 41% confirmed ORR in 2L+ pancreatic cancer and 43% in 2L+ NSCLC, and Verastem reached FDA alignment on the Phase 3 TARGET-D 301 trial design in 1L mPDAC, expected to open by year-end.
The October follow-on offering raised $250.0 million gross, bringing pro forma cash to $422.8 million and extending the runway into 1H 2028.
Offsets: non-GAAP adjusted net loss widened to $72.8 million from $39.1 million on a 137% R&D ramp, and Michael P. Bailey takes over as CEO January 1, 2027 following Dan Paterson's retirement.
• 4d ago AI analysis › Press Release
Verastem Oncology to Participate in Upcoming November Investor Conferences
Verastem Oncology announced management participation in three November investor conferences: Guggenheim Healthcare Innovation (Nov 9), Wolfe Research Healthcare (Nov 10), and Jefferies London Healthcare (Nov 16).
Fireside chat webcasts will be available on the company's website, with replays archived for about 90 days.
The release contains no new financial, clinical, or regulatory information and is a routine IR scheduling notice.
• 7d ago AI analysis › Press Release
Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026
Verastem Oncology announced it will report third quarter 2026 financial results and business updates on Thursday, November 5, 2026, at 4:30 pm ET via conference call and webcast.
The webcast and slides will be available in the Events & Presentations section of the company's investor site, with a replay archived afterward.
This is a scheduling notice only -- no results or guidance are included ahead of the release.
• 18d ago AI analysis › Press Release ● Major ⚠ 2
Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
Verastem Oncology priced a $250 million underwritten offering of 30.9 million common shares at $8.00, plus pre-funded warrants on roughly 312,500 shares at $7.9999.
The deal is expected to close on or about October 15, 2026, with Jefferies, Guggenheim and Cantor as joint book-runners and B. Riley Securities as lead manager.
Proceeds will fund continued clinical development including the VS-7375 program, plus working capital and general corporate purposes; the dilutive effect on the share count is material.
• 26d ago AI analysis › Press Release
Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan
Verastem Oncology appointed board member Michael P. Bailey as President and CEO effective January 1, 2027, succeeding Daniel Paterson, who retires after leading the company as CEO since 2023.
Paterson led the acquisition and FDA accelerated approval of AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent LGSOC and advanced VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, into Phase 2 trials and toward a planned Phase 3 in first-line metastatic pancreatic cancer.
Bailey brings 30+ years of biopharma experience, including a turnaround and 2023 sale of AVEO Pharmaceuticals to LG Chem; his board tenure since May 2026 should support a seamless transition with Paterson remaining on the board and as advisor.
• 26d ago AI analysis › Press Release ● Major ⚠ 3
VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)
Verastem reported the first multi-tumor dataset for VS-7375, its oral KRAS G12D inhibitor, from the Phase 1/2 TARGET-D 101 trial, headlined by a 50% confirmed ORR in 2L pancreatic cancer and a 41% confirmed ORR in the broader 2L+ PDAC population.
Responses appear durable with an 86% disease control rate, 67% six-month PFS, and 80% six-month OS in PDAC, alongside a 43% confirmed ORR in 2L+ NSCLC and a manageable safety profile with only a 2% discontinuation rate.
The company has reached FDA alignment on a chemotherapy-free-inclusive three-arm Phase 3 design in first-line mPDAC, with the trial planned to open by year-end 2026 and Phase 3 CRC/NSCLC starts expected in H1 2027.
With no approved KRAS G12D-targeted therapy on the market, positive Phase 2 data and pivotal-trial momentum materially de-risk the VS-7375 program, though all results remain early and unconfirmed by later-stage trials.
• 26d ago AI analysis › Press Release
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem Oncology granted inducement equity awards under Nasdaq Listing Rule 5635(c)(4): 380,500 RSUs to 24 new employees and options on 50,000 shares to one new employee.
Options carry a $7.90 exercise price, equal to the October 1, 2026 closing price, and awards vest 25% at the one-year anniversary of hire with quarterly vesting over the following three years.
The grants are routine hiring-related compensation under an inducement exception and carry no strategic or financial impact beyond modest dilution.
• 1mo ago AI analysis › Press Release ⚠ 3
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026
Verastem presented new RAMP 201 analyses at IGCS 2026 showing avutometinib plus defactinib activity in KRAS wild-type recurrent low-grade serous ovarian cancer, with ORRs of 22% in NRAS/BRAF-mutated and 18% in KRAS/NRAS/BRAF triple wild-type tumors.
An external control arm analysis versus conventional care showed weighted ORR of 38.7% versus 0% and median PFS of 22.1 versus 6.5 months in KRAS-mutated disease, with statistically significant PFS improvements in both subgroups.
The data support label expansion beyond the approved KRAS-mutated indication but remain exploratory subgroup analyses pending the confirmatory Phase 3 RAMP 301 trial.
• 1mo ago AI analysis › Press Release ⚠ 1
Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer
Verastem announced publication in Gynecologic Oncology of two-year follow-up data from the Phase 2 RAMP 201 study of AVMAPKI FAKZYNJA CO-PACK in recurrent low-grade serous ovarian cancer.
With a median follow-up of 24.9 months, the combination showed a median duration of response of 31.1 months and median PFS of 12.9 months, consistent with the primary analysis that supported the May 2025 FDA accelerated approval for KRAS-mutated recurrent LGSOC.
KRAS wild-type median DoR improved from 9.2 to 12 months with no new safety signals and a 12% AE discontinuation rate; the Phase 3 RAMP 301 confirmatory trial is ongoing, and continued approval remains contingent on its results.
• 1mo ago AI analysis › Press Release ⚠ 2
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
Verastem announced that molecular profiling and tumor biomarker analysis from the Phase 2 RAMP 201 trial of avutometinib plus defactinib in recurrent LGSOC was selected for a late-breaking oral presentation at the IGCS 2026 meeting (Oct 1-3, Montreal).
A seminal oral presentation of the RAMP 201J Japanese-patient study and a poster of an external control arm analysis versus standard-of-care will also be presented on October 2.
No new data were disclosed in this release; the commercial product AVMAPKI FAKZYNJA CO-PACK holds accelerated FDA approval (May 8, 2025) for KRAS-mutated recurrent LGSOC, with the Phase 3 RAMP 301 confirmatory trial ongoing.
• 1mo ago AI analysis › Press Release ⚠ 3
Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
Verastem Oncology will host an investor event and webcast on Wednesday, October 14, 2026, at 8:00 am ET to present initial efficacy and updated safety and tolerability data for VS-7375, its oral KRAS G12D (ON/OFF) inhibitor, across pancreatic, lung, and colorectal cancers.
The data come from the ongoing TARGET-D program, which includes the Phase 1/2 TARGET-D 101 trial and three registration-directed Phase 2 trials in metastatic PDAC, advanced NSCLC, and metastatic colorectal cancer. VS-7375 holds FDA Fast Track Designation in KRAS G12D-mutated PDAC and previously treated NSCLC.
Medical oncologist Dr. Manuel Hidalgo Medina of NYU Langone Health, an investigator in the Phase 1 and Phase 2 trials, will join Verastem management on the webcast. VS-7375 was licensed from GenFleet Therapeutics, with Verastem holding development and commercialization rights outside Greater China.
No new clinical results were disclosed in this release; the October 14 presentation is the catalyst date investors will watch for the first broader safety and efficacy assessment of the asset.
• 2mo ago AI analysis › Press Release
Verastem Oncology to Participate in Upcoming September Investor Conferences
Verastem Oncology management will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston on Sept. 8.
The company is also scheduled to present fireside chats at the Cantor Global Healthcare Conference in New York on September 10 from 8:35-9:05am ET and at the H.C. Wainwright Annual Global Investment Conference on September 14 from 12:00-12:30pm ET.
Live webcasts will be available on the company's website with replays archived for approximately 90 days; the release contains no new clinical, financial, or regulatory information.
• 2mo ago AI analysis › Press Release ● Major
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
Verastem reported Q2 total revenue of $40.1 million, a significant increase driven by $25.1 million in net product revenue for the AVMAPKI FAKZYNJA CO-PACK, compared to $2.1 million in the prior year.
The company strengthened its balance sheet with a non-dilutive royalty financing agreement with Oberland Capital providing up to $75 million, resulting in a pro forma cash position of $201.4 million that extends the runway into the second half of 2027.
Pipeline advances included the first patients dosed in all three Phase 2 registration-directed trials for VS-7375 targeting PDAC, NSCLC, and CRC, alongside the execution of a preclinical evaluation agreement with Erasca.
• 3mo ago AI analysis › Press Release
Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
Verastem Oncology dosed the first patient in TARGET-D 203, a Phase 2 registration-directed trial evaluating VS-7375 in KRAS G12D-mutated metastatic colorectal cancer.
The study will assess VS-7375 as monotherapy and in combination with cetuximab or panitumumab, with a frontline cohort also combining it with chemotherapy.
With this initiation, the company has now begun treatment across all three of its registration-directed Phase 2 trials for VS-7375, covering pancreatic, colorectal, and lung cancers.
• 3mo ago AI analysis › Press Release
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
Verastem Oncology will report its second quarter 2026 financial results on August 6, 2026.
The company will host a conference call and webcast at 4:30 pm ET to discuss the results and provide business updates.
A live audio webcast will be accessible via the Investor Relations section of the company's website.
• 3mo ago AI analysis › Press Release
Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
Verastem Oncology announced the dosing of the first patient in the TARGET-D 202 Phase 2 registration-directed trial of VS-7375 for KRAS G12D-mutated advanced non-small cell lung cancer.
The trial will evaluate VS-7375 monotherapy at 900 mg daily in previously treated patients, including a specific cohort for those with asymptomatic untreated brain metastases.
This marks the second registration-directed Phase 2 trial for VS-7375, following the pancreatic cancer study, with a clinical update expected in the second half of 2026.
• 3mo ago AI analysis › Press Release
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem Oncology issued inducement awards to 31 new employees, consisting of 399,750 restricted stock units and 91,000 stock options.
The options were granted with an exercise price of $4.10, matching the stock's closing price on July 1, 2026.
Vesting for the majority of the awards begins at 25% after one year, with the remainder vesting quarterly over the following three years.
• 4mo ago AI analysis › Press Release ● Major
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
Verastem reported positive preliminary data from the TARGET-D 101 Phase 1/2 trial of VS-7375, showing anti-tumor activity and a favorable safety profile in KRAS G12D-mutated solid tumors.
In heavily pretreated metastatic pancreatic cancer patients, 93% (13/14) achieved a greater than 50% reduction in the CA19-9 tumor marker at the 900 mg dose, with low-grade gastrointestinal adverse events attenuating after the first cycle.
The company announced its intent to collaborate with Erasca to combine VS-7375 with ERAS-0015 and plans to meet with the FDA regarding Phase 3 pivotal trial designs by the end of 2026.
• 4mo ago AI analysis › Press Release ⚠ 2
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
Verastem Oncology reported positive updated data from the Phase 1b/2a RAMP 205 trial evaluating avutometinib plus defactinib combined with chemotherapy in first-line metastatic pancreatic cancer.
The combination achieved an 86% 6-month overall survival rate and a 52% confirmed objective response rate in a cohort of 29 patients, with safety profiles consistent with prior reports.
CEO Dan Paterson stated the company will evaluate future development opportunities and strategic collaborations as overall survival data mature and as the KRAS G12D inhibitor VS-7375 advances.
• 4mo ago AI analysis › Press Release
Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer
Verastem Oncology dosed the first patient in the TARGET-D 201 Phase 2 registration-directed trial of VS-7375 for KRAS G12D-mutated metastatic pancreatic cancer.
The trial evaluates VS-7375 at 900 mg daily as monotherapy and in combination with cetuximab for second-line treatment, with an additional cohort assessing the combination in the frontline setting.
This is the third registration-directed Phase 2 trial for VS-7375, which holds FDA Fast Track designation for both pancreatic and non-small cell lung cancers.
• 4mo ago AI analysis › Press Release
Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program
Verastem Oncology will host an investor conference call on June 23, 2026, to present updated preliminary clinical data for its lead asset VS-7375.
The data covers the Phase 1/2 TARGET-D 101 trial, including safety, tolerability, and pharmacokinetic findings across pancreatic, colorectal, and non-small cell lung cancers.
The company also highlighted recent FDA Fast Track Designations for VS-7375 in pancreatic cancer and NSCLC, reinforcing the asset's development momentum.
• 4mo ago AI analysis › Press Release ● Major
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Verastem Oncology announced that the FDA has granted Fast Track Designation to VS-7375 for the treatment of KRAS G12D-mutated non-small cell lung cancer (NSCLC).
This designation expands the regulatory pathway for VS-7375 beyond its previously granted Fast Track status for pancreatic cancer, targeting a large patient population with limited treatment options.
The company is advancing VS-7375 through Phase 2 registration-directed trials, including TARGET-D 202 in NSCLC, with early data updates expected in the first half of 2026.
• 5mo ago AI analysis › Press Release
Verastem Oncology to Present at Jefferies Healthcare Conference
Verastem Oncology management will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, at 8:10 am ET.
The session will be webcast live and archived on the company’s website for approximately 90 days.
No new clinical or financial data was disclosed in this announcement; it serves as a standard investor relations calendar update.
• 5mo ago AI analysis › Press Release
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors
Verastem Oncology appointed Michael P. Bailey to its Board of Directors, effective immediately.
Bailey is currently the CEO of AVEO Pharmaceuticals, an LG Chem company, and brings over three decades of experience in global pharmaceutical and biotechnology leadership.
Robert Gagnon stepped down from the Board following the end of his term on May 21, 2026.
• 5mo ago AI analysis › Press Release
Verastem Oncology to Present at Upcoming Investor Conferences
businesswire.com • 5mo ago Press Release
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
businesswire.com • 6mo ago Press Release ● Major
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
Verastem Oncology generated $18.7 million in Q1 revenue from its recently launched AVMAPKI FAKZYNJA CO-PACK, marking its first commercial sales following FDA approval.
The company initiated three Phase 2 registration-directed trials for VS-7375 in pancreatic, lung, and colorectal cancers, accelerating its pipeline development.
Verastem ended the quarter with $181.7 million in cash and investments, providing a runway into the first half of 2027, and appointed a new Chief Commercial Officer.
• 6mo ago AI analysis › Press Release
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
Verastem Oncology launched the Reimagine Recurrent LGSOC campaign to drive awareness of AVMAPKI FAKZYNJA CO-PACK, the only FDA-approved treatment for KRAS-mutated recurrent low-grade serous ovarian cancer.
The initiative includes new websites and digital resources designed to educate healthcare professionals and patients about the specific treatment option and manage care expectations.
Approximately 30% of patients with LGSOC have a KRAS mutation, representing the target population for this therapy which received accelerated approval in May 2025.
• 6mo ago AI analysis › Press Release
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
Verastem Oncology announced it will report its first quarter 2026 financial results on Thursday, May 7, 2026.
The company plans to host a conference call and webcast at 4:30 pm ET to discuss the results and provide business updates.
A live webcast and replay will be available on the Investor section of the Verastem website.
• 6mo ago AI analysis › Press Release ● Major
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's Cancers
businesswire.com • 6mo ago 
